KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Gross Margin (2016 - 2025)

Historic Gross Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 84.41%.

  • Halozyme Therapeutics' Gross Margin rose 14500.0% to 84.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.55%, marking a year-over-year increase of 24600.0%. This contributed to the annual value of 84.3% for FY2024, which is 75000.0% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Gross Margin stood at 84.41%, which was up 14500.0% from 85.77% recorded in Q2 2025.
  • Halozyme Therapeutics' Gross Margin's 5-year high stood at 86.42% during Q1 2022, with a 5-year trough of 74.62% in Q3 2023.
  • For the 5-year period, Halozyme Therapeutics' Gross Margin averaged around 81.08%, with its median value being 81.73% (2025).
  • Per our database at Business Quant, Halozyme Therapeutics' Gross Margin tumbled by -81100bps in 2023 and then soared by 86200bps in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Gross Margin stood at 78.84% in 2021, then fell by -3bps to 76.79% in 2022, then rose by 1bps to 77.27% in 2023, then increased by 11bps to 85.89% in 2024, then decreased by -2bps to 84.41% in 2025.
  • Its Gross Margin was 84.41% in Q3 2025, compared to 85.77% in Q2 2025 and 81.73% in Q1 2025.